Coronavirus vaccination in patients with Psoriasis vulgaris under immunosuppressive therapy

ABSTRACT

The COVID-19 disease brought numerous hospitalizations and deaths worldwide, which exerted implications not only for health care professionals of different specialties, but also for the general population in need of medical attention - and psoriasis patients make no exception. The COVID-19 pandemic raised multiple issues of concern such as whether immunosuppressant, including biologic therapy may increase the risk of patients with psoriasis to develop the viral infection or to progress more severely;the possibility of a disease flare-up after discontinuation of immunosuppressive therapy;the safety of COVID-19 vaccination in immunocompromised patients including those on immunosuppressive medications. In this review, we aim to bring attention to the coronavirus vaccination among psoriasis population, a fundamental point of interest for dermatologists, rheumatologists and general practitioners, according to the available guidelines and recommendations. Patient education with respect to SARS-CoV-2 vaccination is of great importance and proper counseling by healthcare professionals is essential for a better understanding of the use of vaccines while on immunosuppressive or biologic therapy.